AZN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AstraZeneca
AstraZeneca (AZN) investors lost money after the Company projected "landmark data" from its Phase III Cardio-TTRansform trial; when the results came in, the trial missed its primary endpoint and the stock declined abruptly. NEW YORK, July 10, 2026 /PRNewswire/ -- On July 9, 2026,...
AstraZeneca (AZN) investors lost money after the Company projected "landmark data" from its Phase III Cardio-TTRansform trial; when the results came in, the trial missed its primary endpoint and the stock declined abruptly. NEW YORK, July 10, 2026 /PRNewswire/ -- On July 9, 2026,...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.